All lobbying filings

AKIN GUMP STRAUSS HAUER & FELD

Lobbying for CHATTEM, INC. DBA OPELLA · Manufacturer of consumer healthcare products.

Filing 1st Quarter - Report

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 20, 2026

Income

$70,000.00

What the client paid this registrant for the period.

Client based in

New Jersey

Official filing document

Government bodies contacted 3

HOUSE OF REPRESENTATIVES
SENATE
U.S. Trade Representative (USTR)

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 4

HR 4273
Over-the-Counter Monograph Drug User Fee Amendments
S 2292
Over-the-Counter Monograph Drug User Fee Amendments
S 2529
A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription …
HR 5371
Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions …

Lobbying activity 2

Health Issues

Issues related to implementation of the OTC Drug Monograph User Fee Program reauthorization and non-prescription drug status - The Over-the-Counter Monograph Drug User Fee Amendments H.R. 4273/S. 2292; S. 2529 - The SMART OTC Act; Division F, Title V of The Continuing Appropriations and Extensions Act, 2026 - H.R. 5371; Issues related to consumer health care products supply chain; Issues related to FY2027 appropriations report language.

Trade (domestic/foreign)

Issues related to imports of unavailable natural resources.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.